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Introduction: Health-related quality of life (HRQOL) has become an important measure
to identify and shape effective and patient-relevant healthcare interventions innovations
through outcomes. Adherence to tuberculosis (TB) treatment is a public health concern.
The main objective of this research is to develop a study design for evaluation of HRQOL
and its association with medication adherence in TB in South Africa.
Methodology: A conceptual framework for HRQOL in TB has been developed to
identify Patient-Reported Outcomes and Quality of Life Database (PROQOLID), (n.d.)
measures for HRQOL and adherence and to generate an endpoint model. Two generic
(SF-12 and EQ-5D-5L), one disease-specific (St. George’s Respiratory Questionnaire)
and one condition-specific (Hospital Anxiety and Depression Scale) measure for HRQOL
and Morisky Medication Adherence Scale for adherence assessment were identified. All
measures are applied in a longitudinal multi-center study at five data collection time
points during standard TB treatment. Statistical analysis includes multivariable analysis.
Change over time in the physical component score of SF-12 is defined as primary
endpoint. Sample size estimation based thereupon has led to a recruitment target of
96 patients. This study is on-going.
Discussion: This is the first longitudinal study in South Africa which evaluates HRQOL
and its association with medication adherence in TB in a comprehensive manner.
Results will help to improve current treatment programs and medication adherence and
will support the identification of sustainable health innovations in TB, determining the
value of new products, and supporting decision making with regard to health policy and
pricing.
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INTRODUCTION
According to the World Health Organization (WHO), health
has a multi-dimensional nature and comprises physical, mental,
and social health domains. (World Health Organization,
1948) Health-related quality of life (HRQOL) is a patient-
reported outcome (PRO) parameter which refers to the
multi-dimensional nature of health directly from the patient
perspective. Tuberculosis (TB) places a significant burden on
the health system of South Africa, which has the highest
prevalence and incidence rates of all 22 high-burden TB
countries worldwide (World Health Organization [WHO], 2015).
Treatment is available in South Africa, however, the incidence
rate is only slowly decreasing and the relapse rate is high. Both
epidemiological parameters may be influenced by HRQOL in
TB. They may also be additionally affected through inadequate
treatment adherence although direct observed treatment (DOT)
has been introduced for supervised treatment monitoring. To
study these associations, further research is required. The study
presented here intends to evaluate HRQOL and its association
with medication adherence in TB in South Africa. To understand
the impact of HRQOL in TB and determinants of medication
adherence, we first conducted a systematic review of the
available literature (Kastien-Hilka et al., 2016). In brief, active TB
impacts HRQOL significantly across different health settings; the
impairment affects physical, emotional, psychological, and social
as well as economical aspects. Although, standard TB treatment
improves all health domains, psychological well-being and
social functioning remained impaired in microbiologically cured
patients after treatment (Muniyandi et al., 2007; Pasipanodya
et al., 2007; Weis and Pasipanodya, 2010; Ralph et al., 2013;
PROQOLID). Most published studies on HRQOL in TB had
a cross-sectional design (Atif et al., 2014b), however, to fully
understand the impairment of HRQOL, TB impact needs to
be assessed over the complete treatment period (Brown et al.,
2015). In our systematic review we identified only 10 studies
which have followed a longitudinal approach; none of them
in a South African environment (Chamla, 2004; Marra et al.,
2008; Dhuria et al., 2009; Maguire et al., 2009; Kruijshaar et al.,
2010; Balgude and Sontakke, 2012; Aggarwal et al., 2013; Ralph
et al., 2013; Atif et al., 2014a; Mamani et al., 2014). Similar
factors as for HRQOL impact medication adherence (World
Health Organization [WHO], 2003; Kastien-Hilka et al., 2016).
Medication adherence “the process by which patients take their
medications as prescribed” (Vrijens et al., 2012). It comprises
the initiation of the treatment (first dose), implementation of
the prescribed dosing regime, and discontinuation of the therapy
(end of therapy), and the persistence (time from initiation
until discontinuation; Vrijens et al., 2012; Lam and Fresco,
2015) Medication adherence is crucial to reach clinical targets
and the causes of non-adherence are multi-factorial (Fairman
and Motheral, 2000; Lam and Fresco, 2015). WHO stated that
“increasing the effectiveness of adherence interventions may
have a far greater impact on the health of the population than
any improvement in specific medical treatment” (World Health
Organization [WHO], 2003). Both HRQOL and adherence are
related to the patient (Cote et al., 2003). A change in adherence
is followed by a change in HRQOL and a relationship between
adherence and HRQOL is existing (Cote et al., 2003; Kastien-
Hilka et al., 2016).
We perform a longitudinal study for evaluating patient-
reported HRQOL and its association with medication adherence
in TB in South Africa. This study is specific to TB and
transferability to other diseases are beyond the scope of this
research. The study will provide information on the health status
of TB patients and their HRQOL; HRQOL outcomes will allow
understanding which health domains are most impacted by TB.
Adherence behavior will be observed from a patient perspective.
This will allow us to identify which health aspects of TB are
influencing adherence and which health domains are impacted
by non-adherence. Since the study is taking place among patients
from South Africa, the cultural and socio-demographic impact
on TB are respected. This article describes the study design and
rationale.
MATERIALS AND STEPWISE
PROCEDURES
Study Aim and Outcomes
The main aim of the study is to evaluate HRQOL and medication
adherence in active TB patients in South Africa. Specific study
outcomes comprise following: to assess TB impact on HRQOL
and its longitudinal changes during standard TB treatment;
to understand patient-reported medication adherence and its
longitudinal changes during standard TB treatment; to evaluate
any influence of socio-demographic aspects on HRQOL and
adherence with regard to gender, age, education, work status and
co-morbidities in sub-group analysis; to assess any association
between changes in HRQOL and changes in adherence and
sputum smear results; to understand if an association between
HRQOL and adherence during standard TB treatment is existing
and which health domains are involved.
The following preparatory steps were undertaken during the
design phase of the study and are described in detail below:
conceptualization of HRQOL in TB; identification of patient-
reported measures applied in HRQOL evaluation and in studies
of adherence to anti-TB standard treatment; selection of HRQOL
and adherence measures capturing all relevant health aspects
of TB; definition of data collection points for HRQOL and
adherence; identification of a primary endpoint on basis of
HRQOL and development of an endpoint model; selection
of study setting; definition of study participant inclusion and
exclusion criteria; development of a rationale for sample size
determination; definition of statistical analysis (PROQOLID;
EuroQol).
Conceptualization of HRQOL in TB
The results of the literature review identified that TB impacts
physical, emotional, psychological, social and economic domains
of HRQOL, with residual impairment still present in each of
these domains even after treatment. Based on these results, a
conceptual framework of HRQOL in TB has been developed
(Figure 1).
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FIGURE 1 | Conceptual framework of HRQOL in TB, developed based on systematic review results.
The physical health domain is mainly described by TB-
related physical and physiological aspects which comprise disease
symptoms, health status, fatigue and physical functioning. There
are also influences of TB treatment due to side effects, pill burden,
and duration of treatment. The mental health domain is mainly
impacted by the psychological and emotional aspects related to
TB which include depression and anxiety, fear of spreading TB,
feelings of anger, health perception of the patient, and patient’s
spirituality. The social health domain we defined by the social
functioning of the patient and the economic burden related to
TB. Social functioning is mainly impacted by social role, social
support, sexual functioning, stigmatization, and social isolation.
The economic burden is influenced by a loss in salary and any
financial burden related to being ill.
Identification of HRQOL and Adherence
PRO Measures in TB
The systematic review yielded 38 studies which applied PRO
measures in HRQOL and adherence: two systematic reviews,
21 cross-sectional studies, 14 longitudinal studies, and one
qualitative study (Table A1 in appendix).
Based on the identified studies, 43 HRQOL and three
adherence PRO measures were extracted, including 34 reported
measures from the systematic reviews of Bauer et al. (2013)
and 17 different HRQOL instruments from Guo et al. (2009;
Tables A2 and A3 in appendix). Overall, the most frequently
applied HRQOL instrument in TB was the generic Short-Form
36 (SF-36), followed by World Health Organization Quality
of Life – BREF (WHOQOL-BREF), EuroQol-5D (EQ-5D)
and disease-specific instruments, namely the Beck Depression
Inventory (BDI), Kessler-10 (K-10) and St. George’s Respiratory
Questionnaire (SGRQ). Our systematic review identified 10
studies applying a longitudinal design in HRQOL evaluation
in TB (Chamla, 2004; Marra et al., 2008; Dhuria et al., 2009;
Maguire et al., 2009; Kruijshaar et al., 2010; Balgude and
Sontakke, 2012; Aggarwal et al., 2013; Ralph et al., 2013; Atif
et al., 2014a; Mamani et al., 2014). Consistent with the results
of the current review, the SF-36 was applied more often than
other PROs to observe longitudinal changes. Next in frequency
were the WHOQOL-BREF, SGRQ, EQ-5D, BDI, as well as
the State-Trait Anxiety Short Form (STAI-6) and Center for
Epidemiologic Studies Depression Scale (CES-D). In addition
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to our literature search, we accessed the database PROQOLID
for HRQOL instruments which are applied in pulmonary and
psychiatric illnesses and linguistically validated for application in
English language in South Africa (PROQOLID). This identified
17 measures (Table A4 in appendix).
Rationale for Selection of HRQOL and
Adherence PRO Measures
A systematic use of generic HRQOL measures in all diseases
supports consistent value judgments and transparent
reimbursement decision making (European Network for
Health Technology Assessment (eunethta), 2013). Two types
of PRO measures are applied in HRQOL evaluations: generic
measures and disease- or condition-specific measures. Generic
measures have the advantage of allowing comparison of quality
of life outcomes across different diseases and can accommodate
effects of co-morbid conditions; they are often applied to
inform health policy maker about allocation of resources
(European Network for Health Technology Assessment
(eunethta), 2013). In contrast to generic measures, disease-
specific instruments comprise disease specific health aspects
(Doward et al., 2010; Deshpande et al., 2011; European Network
for Health Technology Assessment (eunethta), 2013). Disease-
and condition-specific measures may be more sensitive to
changes in HRQOL and may better detect important disease-
related changes over time. Disease- and condition-specific
HRQOL information may be complementary to generic
HRQOL measures, specifically when no effect is observed
with generic measures. However, a recognized and validated
TB-specific HRQOL instrument currently does not exist.
We therefore followed the approach to select generic and
disease- and condition-specific measures which capture all
major HRQOL-related aspects of TB based on our conceptual
framework.
All 43 measures applied in HRQOL studies and three
adherence instruments identified by our literature search as well
as all 17 instruments from the PROQOLID database search were
reviewed. Measures were selected in order to capture physical,
mental, and social health issues of TB. In addition to consistency
with our conceptual framework, selection required that the
respective measures had been validated in TB and linguistically
validated for English in South Africa. Based on these criteria, we
finally selected the SGRQ as a disease-specific measure and the
Hospital Anxiety and Depression Scale (HADS) as a condition-
specific measure. The SGRQ is recommended as a preferred
instrument by the European Medicines Agency [EMA] (2012)
for evaluating quality of life in COPD patients. As a measure
specifically for respiratory diseases, it captures important health
aspects which can be applied to TB. HADS was selected as it
allows evaluation of anxiety and of depression. As a preference-
based and a profile measure, we selected the EQ-5D-5L and
SF-12. Notably, the SF-12 has previously been used in pulmonary
TB patients in South Africa for HRQOL assessment (Louw et al.,
2012).
An ideal adherence measure to assess overall adherence to
medication including initiation, persistance, implementation,
and discontinuation does not exist; therefore, a multi-measure
approach may be considered where direct and indirect adherence
measure are combined (Fairman and Motheral, 2000). Direct
measures such as drug determination in biological fluids or
direct patient observation are often regarded as being the
most reliable and accurate. However, individual changes in
drug metabolism and multidrug intake affect monitoring of
plasma levels, and patient observation is limited to inpatient
settings and clinical trials (Fairman and Motheral, 2000; Nguyen
et al., 2014; Lam and Fresco, 2015). Indirect measures comprise
medication monitoring (such as pill counting) and self-reported
measures; however, medication monitoring is cost intensive
and self-reported measures may be less reliable due to patient
recall, underreported non-adherence and memory bias issues
(Fairman and Motheral, 2000; Lam and Fresco, 2015; Stirratt
et al., 2015). Vrijens et al. (2012) defined adherence measures
for the quantitative assessment of initiation, persistance, and
implementation. Both, initiation and persistance are time-to-
event variables and should be assessed by Kaplan–Meier curves,
median persistence or proportion of persistent patients at a given
time point. Implementation is assessed by a summary statistic
such as the proportion of prescribed drug taken or longitudinally
by electronic databases of drug dosing histories. Each adherence
measure has its advantages and disadvantages and the selection
of adherence measures depends on the attributes, research
objectives and available resources of each study (Lam and Fresco,
2015). The present study focuses on the measurement of HRQOL
and adherence in a real life middle-income setting in a township
of South Africa. The study is purely observational, with no
influence on treatment and follows patients during their TB care.
The available resources of the study and the study environment
do not allow application of direct adherence measures although
they would in principle be the best instruments to measure
patient’s medication taking behavior (Nguyen et al., 2014); Since
DOT is established in South Africa, we decided to apply a self-
reported measure as it allows to identify specific reasons for
being non-adherent (Nguyen et al., 2014; Lam and Fresco, 2015).
Further, a self-reported measure is best applicable to the study
environment and study settings as it is cost-effective, with a
minimum burden to the patient, easy to administer and flexible
in timing and mode of administration. Self-reported adherence
measures have additional advantages; they inform about non-
adherence before adverse clinical outcomes develop and about
adherence determinants such as psychosocial factors (Stirratt
et al., 2015). A gold standard for self-reported, questionnaire-
based adherence measurement does not exist (Fairman and
Motheral, 2000; Nguyen et al., 2014). The Morisky Medication
Adherence Scale (MMAS) is widely used, reliable and valid
and has been applied in TB before (McInerney et al., 2007;
Corless et al., 2009; Lam and Fresco, 2015; Stirratt et al., 2015).
MMAS allows the evaluation of the concept of medication-
taking behaviors, barriers to adherence, and beliefs associated
with adherence (Lam and Fresco, 2015) including forgetfulness
and adverse events (Nguyen et al., 2014). Based on the taxonomy
of adherence by Vrijens et al. (2012) MMAS covers the
implementation and discontinuation phase of adherence. The
assessment of self-reported scales includes the correlation with
an objective adherence measure, and MMAS was correlated with
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pharmacy records and clinical outcomes (blood pressure control)
as comparison measure of adherence (Nguyen et al., 2014).
All four HRQOL measures and the adherence measures are
reliable and validated (PROQOLID; Morisky et al., 2008; Lam
and Fresco, 2015), and the HRQOL measures were linguistically
validated for English in South Africa (Euroqol; PROQOLID; St.
George’s University of London, 2012). All selected measures are
described in detail in the appendix.
Rationale for Study Endpoint Model
An endpoint model for the present study was based on
measurement concepts as reported by Burke from the US FDA
(Burke, 2012). Treatment benefit measurements comprise four
different concepts: disease-defining concepts, proximal disease
and distal disease impact concepts, and disease impact on general
life concepts.
Disease-defining concepts describe clinical signs of a disease.
The impact of these disease-specific clinical signs is reflected
in proximal disease impact concepts of disease symptoms
and somatic sensation. Both disease-defining and proximal
disease impact concepts reflect some aspects of the physical
health domain of the conceptual psychometric framework of
HRQOL. Mental, social, and psychosocial domains of HRQOL
are represented through the distal disease impact concepts.
Distal disease impact concepts include physical, psychological
and social functioning, thereby reflecting additional aspects of
the physical health domain. The disease impact on general life
concept comprises aspects which result from impairment in
distal disease impact concepts, such as impairment of social role
functioning, economic burden and quality of life in general.
Based on the benefit treatment measurement concept of Burke
(Burke, 2012) and based on the psychometric concept of TB-
specific HRQOL, we developed following endpoint concept for
TB (Figure 2):
The selected HRQOL and adherence measures were integrated
into the endpoint concept. The physical health domain of
HRQOL is evaluated by the physical component score (PCS)
of the SF-12 (PCS-12). The change between end of treatment
(EOT) and baseline in the PCS-12 score is defined as the primary
study endpoint. The EQ-5D-5L physical domain and SGRQ
symptoms domain scores represent secondary endpoints. The
mental health domain of HRQOL is assessed by the mental
component score of the SF-12 (MCS-12), the EQ-5D-5L mental
domain, SGRQ activities domain, and HADS. The (psycho-)
social health domain of HRQOL is evaluated by SGRQ impacts
on social activities domain. Other endpoints comprise clinical
data (sputum smear) for presence of active TB and treatment
monitoring as well as medication adherence by application of
MMAS-8. Table 1 provides an overview of endpoints selected
and related instruments applied. The final endpoint model for
evaluation of HRQOL and adherence in TB is presented in
Figure 3.
Study Design and Study Setting
The study is observational in nature with a longitudinal design
including repeated measures of HRQOL and adherence per
study participant. Multiple health facilities are included and the
study has thereby a multi-center design. The highest TB burden
in Cape Town is recorded in the Khayelitsha sub-district. Six
health facilities with the highest TB caseloads per month were
selected. Each health facility has an outpatient TB department.
The caseloads of TB cases for each selected health facility were
provided through the Western Cape Province.
Patient Population and Participant
Recruitment
The patient population comprises patients diagnosed with active
pulmonary TB. TB patients are eligible if their age is 18 years or
older and if they have not received standard TB treatment prior
to this study. Patients are excluded if they are diagnosed with
multidrug-resistant TB (MDR-TB) and extensively drug-resistant
TB (XDR-TB), and/or with HIV co-infection. The eligibility
status of each patient is subject to verification by the responsible
TB nurse of each health facility. Based on a patient information
document, eligible patients are informed about nature, purpose,
potential risks, and benefits of the study. Patients have the
opportunity to decline their participation or to withdraw from
the study at any time point. If an eligible patient agrees to
participate in the study, a written informed consent is obtained
before study start. The sample population is reached by pooling
eligible patients from all study sites.
Study Procedure
Eligible participants receive a 6 months standard TB treatment
with rifampicin, isoniazid, ethambutol, and pyrazinamide at
each health clinic or health center. The drug treatment is local
standard care according to the national TB guideline and DOT
is applied (Department of Health Republic of South Africa,
2014). The treatment is not influenced by this non-interventional
research study. The study evaluates HRQOL and adherence based
on questionnaires completed by patients, who are treated and
managed in the health facility independently from this study.
Most studies evaluating HRQOL longitudinally included data
collection before treatment or at treatment start, at the switch
from the intensive to continuous treatment phase and at EOT
(Chamla, 2004; Marra et al., 2008; Dhuria et al., 2009; Maguire
et al., 2009; Kruijshaar et al., 2010; Balgude and Sontakke, 2012;
Aggarwal et al., 2013; Ralph et al., 2013; Atif et al., 2014a; Mamani
et al., 2014). We decided on a tighter data collection regimen
to monitor changes in HRQOL more closely and included
five different time points over the 6 months treatment period:
beginning of treatment (baseline) and follow-up visits 1–4 after
1, 2, 4, and 6 months (EOT).
Data collection starts when TB treatment is initiated; the four
HRQOL measures and a socio-demographic questionnaire are
applied at baseline (treatment start). The four HRQOL measures
are repeatedly applied at all follow up visits 1–4 together with
the MMAS. Data are collected based on combined completion
of paper questionnaires and face-to-face interviews through
trained field workers. Training of field workers is based on a
Standard Operating Procedure (SOP) specifically written for this
study. Questionnaires are scanned by the field worker for any
missing responses. The patient is asked to provide an answer for
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FIGURE 2 | Endpoint concept for TB based on major HRQOL health domains and on benefit treatment measurement concepts.
TABLE 1 | Lists primary, secondary, and other endpoints included in the
study in order to evaluate longitudinal changes in HRQOL and adherence.
Endpoint (mean difference EOT minus BL) PRO measure
Primary endpoint SF-12 PCS-12
Secondary endpoint SF-12 MCS-12
EQ-5D-5L
SGRQ
HADS
Other endpoint Clinical data (sputum smear)
MMAS-8
the missing response unless the question was intentionally left
unanswered. TB-related clinical data (sputum smear results) are
collected from TB nurses when available during the treatment
period for each patient.
Data Management
All paper-based documents including the questionnaires and
informed consent forms are stored at the University of Cape
Town for a period of 10 years. The HRQOL, adherence and
socio-demographic measures, and sputum smear results data
are transferred to an electronic database independently by two
research team members. Every third questionnaire is entered into
a second database. Both databases are reconciled to minimize
errors related to data entry. All questionnaire responses are
scored according to each questionnaire’s manual instructions.
Scored data are prepared for statistical analysis applying SPSS
software.
Rationale for Sample Size Determination
The primary endpoint is the PCS of SF-12. Walters (2004)
compared four different methods for sample size estimation
using SF-36 as primary endpoint. Since SF-12 has shown
comparable results with SF-36, both measures are seen as similar
and comparable and the methods discussed applicable to SF-12.
We decided to select a method for sample size determination
which is based on the mean difference. The estimation of mean
difference in PCS-12 scores is defined as average mean difference
score between EOT and baseline (BL). We therefore performed
a literature search for studies applying SF-12 or SF-36 as an
outcome measure during TB treatment, and found 10 studies
presenting SF-12 and SF-36 scores (Dion et al., 2004; Guo et al.,
2008; Marra et al., 2008; Babikako et al., 2010; Kruijshaar et al.,
2010; Louw et al., 2012; Bauer et al., 2013; Atif et al., 2014a).
Only two studies reported PCS-36 scores over the 6 months long
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FIGURE 3 | Final endpoint model for evaluation of HRQOL and treatment adherence in PTB, respecting HRQOL domains and disease-defining as well
as proximal and distalmeasurement concepts.
TB treatment, and observed a change in mean score over time
(baseline to EOT) with a mean difference of 4.0 (Babikako et al.,
2010) and of 4.1 (Atif et al., 2014a). The minimal important
difference (MID) for SF-36 and SF-12 is reported with >3 points
by the questionnaire manual (Maruish and Kosinski, 2009).
We therefore assumed a mean difference of 4.0 for our study.
A standard deviation (SD) for PCS-12 was defined with the
value 7 at EOT for PCS-36 (Atif et al., 2014a). Final sample
size was calculated based on a mean difference of 4.0 and a
SD of 7 for mean PCS-12, resulting in a standardized effect
size of 0.57. Using the standardized effect size with a two-
sided 5% level of significance and a 95% power yielded in
an estimated sample size n = 80 subjects. We estimated an
attrition rate of 20% leading to a final sample size n = 96
patients.
Anticipated Results
Based on published HRQOL studies in TB, we expect an
improvement in HRQOL during the course of treatment;
especially physical health aspects are expected to improve.
However, some residual physical impairment has previously
been reported after treatment end, although patients’ were
microbiologically cured. Reported mental and psychosocial
health aspects included depression and anxiety, and social
isolation and stigmatization. We expect to find these aspects
of health impairment reflected in HRQOL outcomes at the
beginning of treatment. As TB treatment requires a long-term
dosing regimen, we expect a decreasing adherence behavior
over the treatment course, although DOT is established and a
requirement in South Africa. Potential pitfalls of our study are
mainly driven by the infrastructure of the health setting in the
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township Khayelitsha, which, however, reflects South African
reality. Patients have no regular access to mobile phones and
interview dates for HRQOL and adherence interviews are difficult
to organize; follow up with the patients is also difficult for
the health facilities. We expect a number of missing interviews
and interviews taken not at the required time points, albeit
around the target interview dates. Our HRQOL and adherence
measures are self-reported measures and reflect a subjective
patient view. Related bias including over- and under-reporting of
both concepts can be expected. This will be consistent with the
individual patient’s TB condition. Experienced pitfalls for future
studies will be discussed as lessons learned from our study.
Statistical Analysis
All statistical analyses are conducted using IBM SPSS Version
22
R©
. Descriptive statistics are calculated for socio-demographic
descriptors of the patient population and all study outcomes.
Study outcomes comprise the means of all HRQOL domain
and total scores, adherence scores and sputum smear results,
and related changes over time. Categorical variables are
described by frequencies, proportions (%) and number of
missing values. Continuous variables (HRQOL, adherence)
are described by the mean and median as measures of
central tendency, first and third quartiles, standard deviation
(SD), minimum (Min) and maximum value (Max), and
number of missing values. Continuous variables are checked
for non-normality with q–q plots and histograms. Outliners
are observed via boxplots; if applicable 5% trimmed means
may be calculated. Ordinal variables representing responses
to questionnaire items are described in the same way as
categorical and/or continuous variables, depending on their
properties. For example, responses to an item with three
answer levels would be described in the same way as a
categorical variable whereas responses to an 11 step (0–10) rating
scale would be described in the same way as a continuous
variable.
Change of each HRQOL measure and of the adherence
measure between baseline and each follow up visit is calculated
based on mean scores. Changes in mean scores between baseline
and EOT are presented as boxplots. Differences between baseline
and each follow up are examined based on significance testing;
choice of tests considers the distribution of the variables involved.
For distributions with no or only limited deviations from
normality, the paired t-test is used, otherwise the Mann–Whitney
U-test. The level of statistical significance is set at 5%, two-sided
for both the paired t-test and Mann–Whitney U-test. Change
in HRQOL mean scores over time (BL, visit 1–4) is further
examined by two-way repeated measure analysis of variance
(ANOVA), for all HRQOL instruments.
Responsiveness of HRQOL measures refers to their ability
to detect important change over time in the concept measured,
even if this change is small. Each change in mean score for each
measure is compared with its reported MID. When the change in
mean score is equal or above the MID, the change is interpreted
as meaningful. Further, the effect size is calculated by dividing the
change in mean score through the standard deviation at baseline
(0.2, 0.5, and 0.8 represent small, medium, and large effect size;
Cohen, 1988; Aggarwal et al., 2013). It is further observed which
health domains improve, worsen, or remain unchanged over
time based on change in mean scores. Hypothesis testing is
applied to HRQOL, adherence and sputum smear outcomes. The
hypotheses testing comprises following assumptions: HRQOL
improves, adherence declines, and sputum smear results improve
over time from baseline to EOT. Hypothesis testing is performed
by repeated measures ANOVA if data are normally distributed
or with the Kruskal–Wallis test for non-normally distributed
data. Sub-group analyses are performed additionally, by gender,
age, ethnicity, marital status, educational and work status, and
co-morbidities.
Additional relationships are assessed for HRQOL, adherence,
and sputum smear results, including sub-groups analyses
according to socio-demographic data. First, the correlations
between all health domains of all HRQOL measures at baseline
are assessed by applying Pearson’s correlation coefficient or
Spearman’s rho coefficient. A correlation matrix is presented.
Second, it is examined how changes in HRQOL and changes in
adherence are associated with changes in sputum smear results
over time. Correlation coefficients are calculated and linear mixed
regression models are estimated. Third, it is examined how
changes in both HRQOL and adherence are linked with the
socio-demographic variables by applying linear mixed regression
models. A final analysis assesses how HRQOL and adherence are
associated with each other, from baseline to EOT, by applying
linear mixed regression models. Adjustments for multiple testing
will be made where sensible. Related issues will be discussed.
DISCUSSION
The impact of TB on patients’ HRQOL has been reported in
international studies including some conducted in high-burden
TB countries but its longitudinal changes have not been assessed
in South African TB patients. South Africa is the country with
the highest prevalence and incidence rate in TB among all
22 high-burden countries (World Health Organization [WHO],
2015). Limited knowledge about adherence behavior during
TB treatment is available, most from qualitative studies. Both
outcomes, HRQOL and adherence, are assumed to impact each
other but this association has not been studied longitudinally so
far. The objective of this research is to perform a study evaluating
HRQOL and its association with medication adherence in
patients with active pulmonary tuberculosis in South Africa. We
developed a conceptual framework for HRQOL in TB capturing
all TB related physical, mental and psycho-social health aspects;
based on a systematic literature search we found a total of 43
different HRQOL and three adherence measures which were
applied in TB. Based on these findings we selected HRQOL
and adherence measures which capture all HRQOL constructs
in TB according to our conceptual framework. The rationale
of PRO measure selection respected the use of generic HRQOL
measures which allow comparison between different diseases and
thus support consistent value judgment and transparency, e.g., in
reimbursement decision making (European Network for Health
Technology Assessment (eunethta), 2013). Further, we included
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disease- and condition-specific instruments which are more
sensitive to change than generic instruments. This ultimately led
to the selection of two generic measures (EQ-5D-5L and SF-
12), one disease-specific (St. George Respiratory Questionnaire)
and one condition-specific measure (HADS). As a patient-
reported adherence instrument, we selected the MMAS. Validity
and reliability of these selected PRO measures, including their
linguistic validation for English for South Africa, is given.
MID was identified from literature for each HRQOL measure
to understand meaningful changes over time. Based on the
conceptual framework and selection of PRO measures, an
endpoint model with the change between EOT and baseline in
the PCS of SF-12 defined as primary endpoint was developed.
PCS score of SF-12 is selected as primary endpoint since TB
has a major impact on the physical health. Based on the
primary endpoint, the required sample size was determined to
be 96 participants. The described protocol is specific to TB,
however, the rationale for selection of HRQOL and adherence
measures may be transferred to other studies applying PRO
measures and might be useful for the development of a general
approach for future studies. Patient-reported HRQOL reflects
the patient perspective, and is an information source for
health service quality and treatment effectiveness which could
support the decision making during reimbursement, access to
medicines and health policy process (McKenna, 2011; Calvert
et al., 2014). A number of clinical trials include PRO measures
for assessing efficacy as endpoint to generate an added value
and to support biochemical endpoints (Doward et al., 2010).
Post-marketing studies apply PRO measures for evaluation of
effectiveness to inform treatment guidelines (Acquadro et al.,
2003). To ensure data quality and evidence reporting, the study
design and methodology of PRO trials are of importance. PRO-
specific rationale and objectives, PRO endpoint specification,
timing of PRO assessment, sample size determination for
HRQOL studies, PRO data collection, and statistical analysis
are key aspects of study design and methodology (Calvert
et al., 2014). We developed our study design according to
these aspects. It is hoped that this study will provide important
information about physical, mental and psycho-social health
aspects of TB in the South African socio-demographic context.
This additional knowledge about TB, which goes beyond well-
known physiological and clinical parameter, should inform
current treatment guidelines for South Africa. Currently, a
number of new TB drugs and diagnostic devices are under
development or in a clinical phase. An integrative knowledge
about HRQOL should assist with evaluating the added value of
newly developed TB drug products and treatment procedures
in comparative effectiveness research (CER) studies. Outcomes
from CER will support resource allocation, reimbursement
decisions, access to medicines and health policy making in
TB in the context of the implementation of National Health
Insurance for South Africa. The evaluation of HRQOL and
its association with adherence in TB using the selected PRO
measures could support future research and development
of a TB-specific measure by reviewing the different health
domains and their items for TB-relevant aspects. Such TB-
specific measure may be integrated into standard care to
monitor TB treatment with an integrative patient-centered
approach.
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